Episode 24

Shen Mi, Tian Tian, and others successfully prevented Shen Hongyuan's new drug release, highlighting the need for improvements in the lymphoma therapy. Shen Hongyuan, criticized by Shen Rong Xian for prioritizing profit over Lv Chuan's mission, was forced to resign from the R&D department and hand over responsibilities to Dr. Gu Mingze.